Skip to main content
OpenTrials
Completed

NCT Number: NCT05862545

Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol)

The aim of the CHOROS ORION study is to describe patients' clinical and self-reported outcomes of treatment with BGF in Italy through effectiveness, clinical and self-reported measures assessed pre- and post-treatment initiation, up to one year of observation period. The study will focus primarily on the change in self-perceived health status in the first 12 weeks of treatment. This will allow to assess the short-term impact of treatment, thus contributing to fill the gap of knowledge from the current available medical literature. Moreover, in order to provide also a broader view, patients will be followed up to 52 weeks, where possible. The study results will be interpreted in the context of an observational study design where multiple factors, in addition to the new treatment, may contribute to the treatment effect.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Obstructive Pulmonary Disease Chronic Disease Disease Attributes Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases

Age range

40 year–120 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Acquaviva delle Fonti, Italy

Loading trial locations.

About this study

The therapeutic goal of chronic obstructive pulmonary disease (COPD) management is mainly reduction of symptoms and severity of exacerbations.Triple therapy (the combination of an ICS, a LABA and a LAMA) in a single fixed-dose combination is a valuable development in the treatment of COPD. On top of treatment adherence enhancement [Gaduzo et al., 2019], trials showed triple therapy improving lung function, Patients-Reported Outcomes (PROs), health-related quality of life, as well as lowering exacerbations and hospitalization rate compared to dual or mono-therapy [Bourbeau et al., 2021; Zheng et al, 2018].

Budesonide/glycopyrrolate/formoterol fumarate, hereafter BGF, is a maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LABA and a LAMA. The availability of single-inhaler triple therapies in routine care may improve symptoms control, reduce exacerbation rate and COPD-related healthcare costs, thus leading to an improvement in patient health status and quality of life. However, real-world studies focusing on PROs are still limited.

The aim of the CHOROS ORION study is to describe patients' clinical and self-reported outcomes of treatment with BGF in Italy through effectiveness, clinical and self-reported measures assessed pre- and post-treatment initiation, up to one year of observation period. The study will focus primarily on the change in self-perceived health status in the first 12 weeks of treatment. This will allow to assess the short-term impact of treatment, thus contributing to fill the gap of knowledge from the current available medical literature. Moreover, in order to provide also a broader view, patients will be followed up to 52 weeks, where possible. The study results will be interpreted in the context of an observational study design where multiple factors, in addition to the new treatment, may contribute to the treatment effect.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female, aged >= 40;
  • Physician-diagnosed COPD;
  • Signed written informed and privacy consent prior to study participation;
  • Patients starting treatment with BGF as prescribed according to the label, local market reimbursement criteria, and AIFA Nota 99;
  • Patients must be able and willing to read and to comprehend written instructions, and to comprehend and complete the questionnaires required by the protocol.

Exclusion criteria

  • COPD due to documented α-1 antitrypsin deficiency;
  • Patients with controlled COPD treated with triple fixed-dose combination in 12 months prior to screening visits;
  • Hospitalisation due to COPD exacerbation within the last 30 days prior to enrolment;
  • Pregnancy or lactation period;
  • Participation in a non-interventional observational trial that might, in the investigator's opinion, influence the assessment for the current study, or participation in any interventional, observational or clinical trial in the last 30 days prior to enrolment.

Treatment and study plan

BGF (budesonide/glycopyrrolate/formoterol fumarate)

Drug

BGF is a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LABA and a LAMA. The decision to start treatment with BGF must be made by the treating physician according to the subjects' medical need and a positive benefit/risk balance. The decision to prescribe BGF must be independent of enrolment into the study, must be determined by the treating physician and should be taken according to the standard of current best medical practice and national guidelines.

Primary outcomes

  1. COPD Assessment Test (CAT) score

    Time frame: baseline, 12 weeks after treatment start

    The change from baseline in COPD Assessment Test (CAT) score after 12 weeks treatment will be analysed using the within person difference between baseline and 12 weeks. Descriptive statistics (mean, median, standard deviation, interquartile range, minimum and maximum) will be provided. The mean change from baseline will be presented along with the 95% CI

Secondary outcomes

  1. Baseline features

    Time frame: Baseline

    To describe the baseline features of patients starting BGF treatment in a real-world setting, in terms of demographics and clinical characteristics, COPD treatment paths and healthcare resource utilization in the previous year.

  2. Impact of COPD on patients' life based on CAT

    Time frame: baseline, 26 and 52 weeks

    To describe the impact of COPD on patients' life, and how it changes over time during the observation period of treatment with BGF, administered as per routine clinical practice. COPD Assessment Test (CAT) questionnaire at baseline and after 26 and 52 weeks after BGF treatment start. In case of patient early withdrawal, CAT questionnaire will also be collected at the end of observation.

  3. Patients' satisfaction to BGF

    Time frame: baseline, 26 and 52 weeks

    9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9) at baseline, 26 and 52 weeks from treatment start. In case of patient early withdrawal, TSQM-9 questionnaire will also be collected at the end of observation.

  4. Patient dyspnoea based on Modified Medical Research Council Dyspnoea Scale (mMRC)

    Time frame: Baseline, 26 and 52 weeks

    To describe patient dyspnoea and how it changes over time during the observation period of treatment with BGF, administered as per routine clinical practice. Modified Medical Research Council Dyspnoea Scale (mMRC) questionnaire at baseline, 26 and 52 weeks from treatment start. In case of patient early withdrawal, mMRC questionnaire will also be collected at the end of observation.

  5. Eosinophil count

    Time frame: baseline, 26 and 52 weeks

    To describe the eosinophil count during the observation period of treatment with BGF, administered as per routine clinical practice. Eosinophil count in peripheral blood at baseline visit, and 26- and 52-week visits, which will occur after BGF treatment start, where available.

  6. Responder Rate based on CAT

    Time frame: 12 weeks

    To describe the Responder Rate based on the CAT after 12 weeks of initiating treatment with BGF as per routine clinical practice. Number and rate of responders of the CAT [MID=2] after 12 weeks of BGF treatment.

  7. Overall change in health status based on Patient Global Impression of Severity (PGIS) questionnaire

    Time frame: Baseline, 12, 26 and 52 weeks

    To assess patient-reported overall change in health status since the start of study treatment and overall global impression of severity during the observation period of treatment with BGF as per routine clinical practice. Single-item patient severity of COPD symptoms using PGIS at baseline, 12, 26 and 52 weeks after BGF treatment start. In case of patient early withdrawal, PGIS questionnaire will also be collected at the end of observation.

  8. Exacerbation rate

    Time frame: 52 weeks

    To describe the occurrence of moderate - severe COPD exacerbations during the observation period of treatment with BGF, administered as per routine clinical practice. Number of moderate - severe COPD exacerbations, occurred during the BGF observation period and Annualized rate of moderate - severe COPD exacerbations during the BGF treatment observation period

  9. Lung function

    Time frame: 52 weeks

    Describe Lung function parameters as measured at baseline and 52-week visit, available as per routine clinical practice.

  10. OCS use

    Time frame: 52 weeks

    To describe the Oral Corticosteroids (OCS) use during the observation period of treatment with BGF, administered as per routine clinical practice, and in the previous year. OCS use during the observation period after BGF treatment start, and OCS use in the 52 weeks before BGF treatment start.

  11. HCRU

    Time frame: 52 weeks

    To describe the healthcare resource utilization related to COPD during the observation period of treatment with BGF, administered as per routine clinical practice, and in the previous year. The number of GP/specialist visits, ER admissions, and hospitalizations (along with duration) related to COPD during the BGF observation period and the 52 weeks prior baseline will be described. The annualised rate of utilization per each type will be calculated.

  12. Safety (frequency of all AEs, SAEs, AEs related to BGF and Special Situations during the observation period)

    Time frame: 52 weeks

    To describe safety profile of BGF during the observation period Absolute and relative frequency of all AEs, SAEs, AEs related to BGF and Special Situations during the observation period will be calculated. Moreover, the count of such events will be provided. Descriptive statistics will also be provided for severity, seriousness criteria (where applicable), relation grade with BGF, action taken and outcome.

Other outcomes

  1. Relation between patient CAT score (dependent variable of interest) and patient baseline characteristics

    Time frame: 52 weeks

    To describe the relation of baseline characteristics and the impact of COPD on patients' life during the observation period of treatment with BGF, administered as per routine clinical practice

  2. Baseline variables associated with exacerbations

    Time frame: 52 weeks

    To describe the relation of baseline characteristics and occurrence of COPD exacerbations during the observation period of treatment with BGF, administered as per routine clinical practice. The analysis will be performed in steps. Firstly, univariate Poisson regression models for the estimated impact on exacerbations occurrence during the observation period will be estimated independently considering the baseline variables (age, sex, BMI, smoking status, eosinophil count in peripheral blood, COPD phenotype and years from diagnosis, number of previous MACEs, number of moderate - severe COPD exacerbations in the year before BGF treatment start, and OCS use in the year before BGF treatment start). Then a multivariate Poisson regression model will be estimated including relevant variables (i.e. with a significant estimated coefficient), as evaluated through the single univariate regression models and the number of exacerbations during follow up

  3. Occurrence of Major Cardiovascular Events (MACE)

    Time frame: 52 weeks

    To describe the occurrence of Major Cardiovascular Events (MACE) during the observation period of treatment with BGF, administered as per routine clinical practice Descriptive statistics of the time to first MACE (cardiovascular death, myocardial infarction, or ischemic stroke) occurred during the BGF treatment observation period will be computed by means of a Kaplan-Meier analysis. In case patients do not experience a MACE, they will be considered as censored observations and time until the end of their observation will be calculated. In addition, the count of MACE and the absolute and relative frequency of patients with a MACE will be calculated during the BGF treatment observation period.

  4. Mortality rate

    Time frame: 52 weeks

    To assess the mortality during the observation period of treatment with BGF, administered as per routine clinical practice Descriptive statistics of the time to death occurred during the observation period after BGF treatment start will be computed by means of a Kaplan-Meier analysis. The count of mortality events during the observation period will be reported too.

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

Outcomes in Real-life After Initation Of treatmeNt With Trixeo (Budesonide / Glycopyrronium / Formoterol), a Non-interventional, Multi-centre, Prospective Cohort Study in Italian Routine Care Setting

Acronym: CHOROS ORION

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
May 17, 2023
Registry last updated
Mar 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.